Belite Bio (BLTE) Accumulated Depreciation & Amortization (2021 - 2025)
Belite Bio (BLTE) recorded quarterly Accumulated Depreciation & Amortization of $192000.0 in Q4 2025, up 540.0% quarter-over-quarter from $30000.0 in Q4 2024, and up 540.0% on a YoY basis from $30000.0 in Q4 2024.
Belite Bio (BLTE) Accumulated Depreciation & Amortization (2021 - 2025) Analysis & Trends
Belite Bio's Accumulated Depreciation & Amortization history runs 5 years deep, the most recent figure standing at $192000.0 for Q4 2025.
- In Q4 2025, Accumulated Depreciation & Amortization rose 540.0% year-over-year to $192000.0; the TTM figure through Dec 2025 stood at $192000.0 (up 540.0% YoY), while the FY2025 annual figure was $192000.0, up 540.0% from the prior year.
- Accumulated Depreciation & Amortization was $192000.0 for Q4 2025 at Belite Bio, up from $30000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $192000.0 in Q4 2025 to a low of -$487000.0 in Q4 2022.
- Historically, Accumulated Depreciation & Amortization has averaged -$128800.0 across 5 years, with a median of $30000.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Accumulated Depreciation & Amortization sank 1136.17% in 2022, then soared 540.0% in 2025.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $47000.0 in 2021, then tumbled by 1136.17% to -$487000.0 in 2022, then gained by 12.53% to -$426000.0 in 2023, then jumped by 107.04% to $30000.0 in 2024, then jumped by 540.0% to $192000.0 in 2025.
- The last three Accumulated Depreciation & Amortization figures came in at $192000.0 (Q4 2025), $30000.0 (Q4 2024), and -$426000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 192,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2023 | -426,000.00 |
| Dec 31, 2023 | -426,000.00 |
| Dec 31, 2022 | -487,000.00 |
| Dec 31, 2022 | -487,000.00 |
| Dec 31, 2021 | 47,000.00 |
| Dec 31, 2021 | 47,000.00 |